REVVITY, INC. Goodwill & Intangibles Disclosure
| Life Sciences | Diagnostics | Consolidated | ||||||||||||||||||
| (In thousands) | ||||||||||||||||||||
| Balance at December 31, 2023 | $ | 4,587,938 | $ | 1,945,612 | $ | 6,533,550 | ||||||||||||||
| Foreign currency translation | (46,471) | (23,460) | (69,931) | |||||||||||||||||
| Balance at December 29, 2024 | 4,541,467 | 1,922,152 | 6,463,619 | |||||||||||||||||
| Foreign currency translation | 105,495 | 44,379 | 149,874 | |||||||||||||||||
| Other | 98,000 | (98,000) | — | |||||||||||||||||
Balance at December 28, 2025 | $ | 4,744,962 | $ | 1,868,531 | $ | 6,613,493 | ||||||||||||||
| December 28, 2025 | December 29, 2024 | ||||||||||
| (In thousands) | |||||||||||
| Patents | $ | 27,592 | $ | 27,808 | |||||||
| Less: Accumulated amortization | (26,524) | (26,293) | |||||||||
| Net patents | 1,068 | 1,515 | |||||||||
| Trade names and trademarks | 150,103 | 142,588 | |||||||||
| Less: Accumulated amortization | (102,234) | (87,824) | |||||||||
| Net trade names and trademarks | 47,869 | 54,764 | |||||||||
| Licenses | 27,561 | 27,164 | |||||||||
| Less: Accumulated amortization | (19,849) | (17,855) | |||||||||
| Net licenses | 7,712 | 9,309 | |||||||||
| Core technology | 1,624,925 | 1,561,831 | |||||||||
| Less: Accumulated amortization | (921,325) | (735,532) | |||||||||
| Net core technology | 703,600 | 826,299 | |||||||||
| Customer relationships | 2,870,384 | 2,807,909 | |||||||||
| Less: Accumulated amortization | (1,283,630) | (1,058,875) | |||||||||
| Net customer relationships | 1,586,754 | 1,749,034 | |||||||||
| Net amortizable intangible assets | $ | 2,347,003 | $ | 2,640,921 | |||||||
Want the next REVVITY, INC. goodwill & intangibles disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment REVVITY, INC.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 24, 2026 | Showing above |
| 2024 | Feb 25, 2025 | |
| 2023 | Mar 1, 2023 | |
| 2022 | Mar 3, 2022 | |
| 2021 | Mar 2, 2021 | |
| 2019 | Feb 25, 2020 | |
| 2018 | Feb 26, 2019 | |
| 2017 | Feb 28, 2017 | |
| 2016 | Mar 1, 2016 | |
About Goodwill & Intangibles Disclosures
Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.
Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.